Budesonide Market to Undertake Strapping Growth During 2017 - 2025 23rd June 3 | Page 2

entocortec, uceris, pulmicort, pulmicort flexhaler, pulmicort respules, and rhinocort. It's also one of
the drugs found in the inhaler symbicort, used to treat COPD and asthma. Budesonide is expected
to grow at significant CAGR in near future.
Global Budesonide Market: Segmentation
The global demand of global budesonide can be segmented on the basis of product type,
application and region basis. On the basis of product type budesonide market can be segmented
as aerosol, sprays, inhalants, and suspension, pill&rectal forms. On the basis application
budesonide market is segmented to hospital, pharmacy, clinic and others. On the basis of region,
budesonide market is segmented into North America, Latin America, Europe, Asia Pacific and
Middle East and Africa.
A sample of this report is available upon request @
http://www.persistencemarketresearch.com/samples/13456
Global Budesonide Market: Regional Overview
Asia pacific have significant high market share in budesonide market as compared to others owing
to increasing population as well as increasing pollution issue in this region especially in the
countries such as India and China. China is expected to dominate budesonide market in the near
future. The market size of budesonide in Asia Pacific is expected to keep growing in next few
years. The North America is expected to Experience significant growth in coming years following
Europe. Latin America and Middle East & Africa is projected to experience stagnant growth rate
during the forecast period.
To view TOC of this report is available upon request @
http://www.persistencemarketresearch.com/toc/13456
Global Budesonide Market: Key Players
Few market players in global budesonide are Pfizer, Sandoz, Cipla, Cosmo Pharmaceuticals,
Takeda, Manus Aktteva Biopharma LLP, Abbott, Lunan Better Pharmaceutical, Novartis, Mylan,
Novartis, Skyepharma, AstraZeneca AB, Wellcome Australia Ltd, AstraZeneca plc, AstraZeneca
Australia, Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus, Synmosa Biopharma
Corporation.